Risk of seizures in neonates with hypoxic-ischemic encephalopathy receiving hypothermia plus erythropoietin or placebo

Hannah C. Glass,Courtney J. Wusthoff,Bryan A. Comstock,Adam L. Numis,Fernando F. Gonzalez,Nathalie Maitre,Shavonne L. Massey,Dennis E. Mayock,Ulrike Mietzsch,Niranjana Natarajan,Gregory M. Sokol,Sonia L. Bonifacio,Krisa P. Van Meurs,Cameron Thomas,Kaashif A. Ahmad,Patrick J. Heagerty,Sandra E. Juul,Yvonne W. Wu
DOI: https://doi.org/10.1038/s41390-022-02398-w
IF: 3.953
2022-12-06
Pediatric Research
Abstract:An ancillary study of the High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) trial for neonates with hypoxic-ischemic encephalopathy (HIE) and treated with therapeutic hypothermia examined the hypothesis that neonates randomized to receive erythropoietin (Epo) would have a lower seizure risk and burden compared with neonates who received placebo.
pediatrics
What problem does this paper attempt to address?